Industry insights: Is biopharma ready for a sustainable future?

Cytiva helps biopharma companies worldwide develop advanced medicines. In this interview, Emmanuel Abate, President of Genomic Medicine and Head of Sustainability at Cytiva, talks about the company’s commitment to advancing biopharma while keeping sustainability at the forefront.

Abate shares insights from the Global Biopharma Sustainability Review published by Cytiva, which revealed that sustainability is a significant focus for 62% of biopharma companies. However, managing Scope 3 emissions and complex supply chains remains an ongoing and complex challenge. Join us to find out what the industry can do to overcome this hurdle.

Speakers:
Emmanuel Abate, President of Genomic Medicine and Head of Sustainability and Corporate Social Responsibility, Cytiva

Emmanuel Abate works to bring out the best in his team so they can better serve the scientific community working on tomorrow’s medical breakthroughs. He leads the genomic medicine business, which includes the recently acquired Precision NanoSystems, as well as a diverse portfolio focused on nucleic acids, viral vectors, and cell therapies. Abate also oversees the company-wide sustainability and corporate social responsibility strategy.

We surveyed 800 biopharma professionals from 18 different countries to assess the progress the industry has made relating to sustainability. Dive into our full Biopharma Sustainability Review for more insights. Visit: https://cytiva.link/hdpg3